Your browser is no longer supported. Please, upgrade your browser.
Baudax Bio, Inc.
Index- P/E- EPS (ttm)-5.67 Insider Own1.70% Shs Outstand70.14M Perf Week-27.70%
Market Cap59.39M Forward P/E- EPS next Y-0.41 Insider Trans2.10% Shs Float62.58M Perf Month-32.94%
Income-76.10M PEG- EPS next Q-0.19 Inst Own17.30% Short Float6.97% Perf Quarter-46.70%
Sales0.50M P/S118.77 EPS this Y-12.90% Inst Trans39.54% Short Ratio1.08 Perf Half Y-28.32%
Book/sh-0.47 P/B- EPS next Y34.90% ROA-108.80% Target Price- Perf Year-72.74%
Cash/sh0.42 P/C1.96 EPS next 5Y- ROE196.00% 52W Range0.90 - 4.95 Perf YTD-17.67%
Dividend- P/FCF- EPS past 5Y- ROI1335.50% 52W High-83.20% Beta-
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin- 52W Low-7.61% ATR0.09
Employees57 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)28.11 Volatility11.37% 8.37%
OptionableYes Debt/Eq- EPS Q/Q24.50% Profit Margin- Rel Volume1.12 Prev Close0.91
ShortableYes LT Debt/Eq- EarningsMay 05 BMO Payout- Avg Volume4.02M Price0.83
Recom1.70 SMA20-23.85% SMA50-33.34% SMA200-54.80% Volume4,504,350 Change-8.43%
May-15-20Initiated JMP Securities Mkt Outperform $13
May-05-21 07:00AM  
Apr-29-21 07:00AM  
Apr-26-21 07:00AM  
Apr-12-21 08:32AM  
Apr-01-21 07:00AM  
Mar-10-21 07:00AM  
Mar-08-21 07:00AM  
Mar-02-21 07:00AM  
Feb-17-21 12:32AM  
Feb-16-21 07:00AM  
Feb-10-21 08:05AM  
Feb-08-21 03:24PM  
Feb-01-21 10:05PM  
Jan-21-21 09:29AM  
Jan-06-21 07:00AM  
Dec-17-20 07:00AM  
Dec-08-20 08:40AM  
Dec-07-20 05:17PM  
Nov-30-20 04:05PM  
Nov-23-20 08:00AM  
Nov-20-20 07:00AM  
Nov-19-20 07:00AM  
Nov-11-20 05:30AM  
Nov-09-20 07:15AM  
Nov-02-20 07:05AM  
Oct-20-20 07:00AM  
Oct-02-20 04:05PM  
Sep-18-20 07:35AM  
Sep-01-20 03:30PM  
Aug-25-20 04:05PM  
Aug-20-20 05:57PM  
Aug-17-20 12:28PM  
Aug-10-20 07:15AM  
Aug-06-20 04:05PM  
Jul-30-20 04:05PM  
Jul-20-20 07:00AM  
Jul-05-20 02:53PM  
Jul-03-20 03:25PM  
Jun-15-20 07:00AM  
Jun-01-20 07:00AM  
May-18-20 06:12AM  
May-08-20 07:00AM  
May-05-20 07:00AM  
May-01-20 04:05PM  
Apr-29-20 10:02AM  
Apr-23-20 07:00AM  
Apr-07-20 08:00AM  
Apr-03-20 06:40PM  
Mar-26-20 11:35AM  
Mar-24-20 09:15AM  
Mar-23-20 04:20PM  
Mar-04-20 11:43AM  
Feb-20-20 04:05PM  
Feb-19-20 06:16PM  
Feb-13-20 04:08PM  
Jan-22-20 07:00AM  
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Casten Richard SChief Financial OfficerMar 15Buy1.4125,00035,180125,000Mar 16 05:06 PM